Patients who are going to undergo highly invasive abdominal surgery listed above. highly invasive abdominal surgery
Conditions
Interventions
Drug: Super Synbiotics LBG-P (a supplement for medical use), which contains Lactobacillus casei Shirota (100-1000 million) and Bifidobacterium breve Yakult (100-1000 million) per one packet as probiot
Sponsors
Yokoyama Yukihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are going to undergo highly invasive abdominal surgery in Nagoya University Hospital. Highly invasive surgeries in this study include followings: Major hepatectomy Hepatopancreatoduodenectomy Pancreatoduodenectomy Distal pancreatectomy with celiac axis resection Subtotal esophagectomy Other surgeris that are considered as highly invasive by primary investigator Target diseases: every diseases that require highly invasive surgery (irrespective of malignancy) Patients with the age equal to or more than 20
Exclusion criteria
Exclusion criteria: Patients who reject participation for this study Patients wiht severe cognitive disease Other patients who are considered not eligible for this study (by the decision of investigators)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare the relative changes of intestinal micribiota profile, fecal organic acid concentrations, and pH before and after the intake of probiotics, prebiotics, and synbiotics. | — |
Secondary
| Measure | Time frame |
|---|---|
| Compare the intestinal microbiota profile, fecal organic acid concentrations, and pH after two weeks intake of probiotics, prebiotics, and synbiotics. | — |
Contacts
Public ContactYukihiro Yokoyama
Aichi Medical University
Outcome results
None listed